Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method
概览
- 阶段
- 不适用
- 干预措施
- Pseudomonas aeruginosa colonization infection
- 疾病 / 适应症
- Bronchiectasis
- 发起方
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 入组人数
- 150
- 试验地点
- 4
- 主要终点
- Acute exacerbations and mortality
- 状态
- 招募中
- 最后更新
- 3个月前
概览
简要总结
Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi and is associated with chronic and frequently purulent expectoration, multiple exacerbations and progressive dyspnea. Bronchiectasis has a large heterogeneity. Different patients with bronchiectasis may have different etiology, clinical manifestations, and imaging features. Previous studies showed that there are significant relationship between the airway microbiome and the severity of the disease. For example, patient with airway Pseudomonas aeruginosa colonization has heavier symptoms, heavier severity, poorer quality of life, more acute exacerbations, and worse prognosis. A large number of studies have reported that long-term treatment of low-dose macrolides such as azithromycin or clarithromycin has anti-inflammatory and immunomodulatory effects, which can improve the clinical symptoms and disease progression of various chronic airway diseases, such as diffuse panbronchiolitis, chronic obstructive pulmonary disease, bronchiectasis. Both the 2017 European Respiratory Society guidelines and the 2019 British Thoracic Society Guideline recommend macrolide drugs for the treatment of chronic Pseudomonas aeruginosa colonization bronchiectasis or frequent acute exacerbations bronchiectasis, but the specific mechanism is unknown.This study is based on omics methods (Microbiology and Metabolomics) to deeply explore the composition of airway and gut microbiota in patients with bronchiectasis, the factors affecting the colonization of Pseudomonas aeruginosa and the mechanism of macrolides in the treatment of bronchiectasis.
This project is a multicenter clinical study involving patients with bronchiectasis from Wuhan Union Hospital, Guizhou Provincial People's Hospital, and Yichang Central People's Hospital. Patients with bronchiectasis were recruited according to the inclusion and exclusion criteria. Clinical data were collected from these patients (including demographic information, clinical characteristics, pulmonary function, and lung imaging), along with spontaneously expectorated sputum, feces, and peripheral blood, and the patients were followed for 24 months. The microbiome, metabolome, and cytokines in sputum and feces were assessed, as well as cytokines, inflammatory mediators, and metabolites in peripheral blood.
Through the above methods,investigators further understand the mechanism affecting progression of bronchiectasis and some factors that lead to the colonization of Pseudomonas aeruginosa, as well as mechanisms of macrolides in the treatment of bronchiectasis.
详细描述
Clinical information: Demographic information,blood test results,lung function,severity of disease was evaluated using the E-FACED and the Bronchiectasis Severity Index (BSI).The severity of dyspnea was assessed using the Medical Research Council (MRC) grade, and lung radiological severity was assessed using the modified Reiff score and Bhalla score. Sputum collection: We collect sputum samples from patients with bronchiectasis. We divided into two parts from each sputum sample, one part was immediately stored -80℃ for microbiota sequencing. The other part was diluted with PBS and centrifuged at 12000g for 5 minutes, and the supernatant was stored at -80°C for measurement of inflammatory factors, oxidative stress and other markers. Stool collection: We collect stool samples from patients with bronchiectasis.Fresh stools were processed in the laboratory within 30 min after collection and stored at -80°C until analysis. Peripheral blood collection: We collect peripheral blood samples from patients with bronchiectasis to detect inflammatory mediators and so on.
研究者
Wang xiaorong
Attending physician
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
入排标准
入选标准
- •18 years or older
- •Bronchiectasis confirmed by high-resolution computed tomographic scan(HRCT)
- •Chronic expectoration with ability to provide a sputum sample at the study visit
- •Provision of written informed consent
排除标准
- •Traction bronchiectasis
- •Lack of important clinical information
研究组 & 干预措施
Pseudomonas aeruginosa colonization group
Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
干预措施: Pseudomonas aeruginosa colonization infection
Non-Pseudomonas aeruginosa colonization group
No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
干预措施: Pseudomonas aeruginosa colonization infection
Before treatment with macrolides
Before treatment with macrolides in patients with bronchiectasis
干预措施: Macrolides
After treatment with macrolides
After 6 months of treatment with macrolides for patients with bronchiectasis
干预措施: Macrolides
结局指标
主要结局
Acute exacerbations and mortality
时间窗: February 10, 2026
The number of acute exacerbations and outcome (death or survival) of patients with bronchiectasis after one year.
次要结局
- Lung function(February 10, 2026)
- Symptoms assessment(February 10, 2026)
- Stool and sputum microtioba(February 10, 2026)